Neutralizing GM-CSF autoantibodies are observed at high levels in autoimmune PAP patients (17, 34) but not in those with congenital or secondary PAP, other respiratory diseases, or healthy people (21, 44). This evidence concerns the gene CSF2 and respiratory system disorder.